I have over 30 years of broad Pharmaceutical and Biotechnology industry experience including business development, operations, corporate and product marketing, sales, fundraising and product development. Most recently I was SVP, Corporate Development at Protagonist Therapeutics responsible for licensing, alliance management, and various operational activities. I led the transaction to partner a preclinical program, PTG-200, with Janssen and participated in the completion of a Series C, IPO and follow-on offering. Previously, I was a Founder and CEO of Trenovus, Inc. a start‐up biotechnology company focused on developing novel inhibitors of heterotopic ossification present in a number of conditions including Ankylosing Spondylitis and Fibrodysplasia Ossificans Progressiva. Prior to Trenovus, I was Vice President, Business Development of FibroGen where I was responsible for all licensing and M&A activity including ongoing partner Alliance Management. I executed a large number and variety of transactions while at FibroGen including in- and out-licensing agreements, feasibility agreements, manufacturing agreements, and acquisitions. Most significantly, I led the historic out‐licensing of HIF prolyl hydroxylase inhibitors for anemia indications to Astellas for the European, South Africa and Middle East territories in February 2006. Prior to joining FibroGen in 2001, I was at the drug delivery company Aradigm, where he was a Director of Business Development and Marketing from 1997 to 2001. Since 1986, I’ve held sales, marketing, and product development positions at Penederm (Mylan), Ciba Geigy (Novartis), Bristol‐Myers Squibb, and Marion Laboratories (Sanofi). I completed my undergraduate studies at Oakland University with a B.S. in biology and hold an M.B.A. from the University of Chicago Booth School of Business and have been invited to speak at numerous licensing events.